SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST

(FBIOyF) Departamento de Bioquímica Clínica

URI permanente para esta comunidad

https://rephip.unr.edu.ar/handle/2133/2568

Examinar

Examinando (FBIOyF) Departamento de Bioquímica Clínica por Autor "Acosta, Andrea"

Mostrando 1 - 1 de 1
  • Miniatura
    ÍtemAcceso Abierto
    Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma
    (American Society for Microbiology, 2023-11-08) Perichon, Armando M.; Acosta, Andrea; Di Tullio, Liliana; Munuce, María José; Pezzotto, Stella; Bottasso, Oscar; http://orcid.org/0000-0002-8472-7965
    The use of convalescent plasma (CP) for hospitalized patients with SARSCoV-2 infection might be a useful option in certain settings. Soon after the outbreak of COVID-19, the National Ministry of Health of Argentina recommended the use of CP transfusion for hospitalized patients with COVID-19 disease. Between 1 June and 3 October 2020, 480 patients, excluding those on invasive mechanical ventilation (IMV), received at least one CP infusion in the province of Santa Fe. We aimed to find factors associated with mortality among this cohort of patients. The median age was 60 years (interquartile range: 49–69 years) and 320 (66.7%) were males. Most of these patients (93.75%) received a single CP infusion, 82.1% and 95.6% before day 4 and day 7 of hospitalization, respectively. Anti-SARS-CoV-2 titers were determined in the CP units administered using Elecsys Anti-SARS-CoV-2 S assay. At 28 days of follow-up, 250 patients were discharged (52.1%), 131 (27.3%) remained hospitalized without and 16 (3.3%) with oxygen requirement, 27 (5.6%) were on IMV, and 56 (11.7%) had died. In the multivariate logistic regression analysis, the factors significantly associated with 28-day mortality were (i) requirement of IMV, (ii) the administration of CP after the third day of hospitalization, (iii) age, and (iv) number of comorbidities. The qualitative and quantitative analyses of antibodies against SARS-CoV-2 in the infused CP were not associated with mortality. Our findings may imply a seemingly favorable effect of CP administration among patients with severe COVID-19 disease when infused sooner after hospitalization.